Drugs / GM-K562 cell vaccine
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00301093 | Sep 2005 → May 2007 | leukemia | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00363649 | Sep 2006 → Sep 2017 | leukemia | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GM-K562 cell vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00301093 ↗ |
| Action | Deplete | “Vaccines made from a person's cancer cells may help the body build an effective immune response to kill cancer cells.” NCT00363649 ↗ |
| Modality | Vaccine | “Vaccines made from gene-modified cancer cells may help the body build an effective immune response to kill cancer cells.” NCT00301093 ↗ |
| Route | Subcutaneous | “Patients receive GM-K562 subcutaneously” NCT00301093 ↗ |